Cognium, a silk-protein dietary supplement, has not been shown to treat memory loss, cognitive impairment, dementia, or Alzheimer's disease. Its key trial studied healthy adults and excluded people with neurological disorders, so the findings do not establish a treatment for those conditions. The study offers a limited signal about test performance in healthy adults. Important questions remain about the studied ingredient, Cognium's current dose, and how the product's claims should be interpreted.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is Cognium labeled to do?
- What did the silk-protein trial find?
- Why doesn't the study answer the memory-loss question?
- Does Cognium's label match the studied dose?
- How should readers assess the claims?
What is Cognium labeled to do?
Natrol markets Cognium memory for memory and recall in healthy adults. The current Natrol product page does not present it as a treatment for cognitive impairment, dementia, or Alzheimer's disease.
That distinction matters for anyone already experiencing memory problems. Evidence that a supplement may improve test scores in healthy volunteers cannot establish that it slows disease, restores lost abilities, or helps someone with a neurological disorder.
What did the silk-protein trial find?
A 2018 randomized, double-blind, placebo-controlled trial tested a proprietary silk fibroin enzymatic hydrolysate. This is silk protein broken into smaller components through an enzyme-based process. Healthy adults received 280 to 600 milligrams daily for three weeks.
Participants averaged about 55 years old, and the researchers reported improvements on certain test-based memory outcomes, according to the original study in Nutrients. These results suggest a possible short-term effect worth studying further. They do not show whether participants noticed a meaningful change in daily life or whether any benefit would continue beyond three weeks.
Why doesn't the study answer the memory-loss question?
The trial excluded people with neurological disorders. It therefore cannot tell readers whether the ingredient helps someone with dementia, Alzheimer's disease, cognitive impairment, or unexplained memory loss. The evidence also has several practical limits.
Only 61 of 76 randomized participants completed the trial, and all reported studies involved Korean populations. The ingredient supplier, BrainOn, funded the research. Together, these limits reduce confidence that the findings would apply broadly or persist over time. They also leave unanswered whether the supplement affects disease-related memory decline rather than performance among healthy adults.
Does Cognium's label match the studied dose?
Natrol's current directions call for two tablets daily. Each tablet contains 100 milligrams of "Silk Protein Hydrolysate Complex," for a total labeled amount of 200 milligrams. The 2018 trial reported significant effects at doses above 280 milligrams daily of its specifically prepared hydrolysate.
The available label information does not establish that Cognium's current complex is equivalent to the studied material. This is more than a numerical mismatch. Ingredient preparation can matter, so readers should not assume that 200 milligrams of the labeled complex reproduces results from 280 to 600 milligrams of a proprietary research ingredient.
How should readers assess the claims?
The product carries the required disclaimer that FDA has not evaluated its claims and that it is not intended to diagnose, treat, cure, or prevent disease. FDA guidance says supplement manufacturers—not FDA preapproval—are responsible for ensuring claims are truthful and not misleading. A separate FDA "no questions" response involving Bombyx mori silk fibroin does not resolve Cognium's effectiveness. That notice concerned another company's ingredient for use as a food surface-finishing agent, not approval of Cognium or proof that silk protein treats memory loss.
A purchaser also challenged Cognium's supporting research in Vitello v. Natrol, alleging that two of nine cited studies had been retracted, including one over data fabrication or falsification. The Eighth Circuit's 2022 decision affirmed dismissal because her use of Cognium as an Adderall substitute defeated her claimed loss—not because the court determined whether those research allegations were true. Before relying on Cognium for existing memory problems:.
- Compare the label's intended users with the population actually studied.
- Notice that the current daily amount is below the trial's reported effective range.
- Do not treat supplement labeling or a food-use GRAS notice as evidence of disease treatment.
- Discuss ongoing or worsening memory concerns with a healthcare professional rather than using this trial as proof that Cognium addresses their cause.
